Zenas BioPharma Inc. Common Stock (ZBIO)

About ZBIO

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus eryt…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

167

Website

zenasbio.com/

Fundamentals

1-day range

$31.19$32.38

Market cap

$1.97B

P/E (trailing)

—

P/E (forward)

-6.71

EPS (trailing)

$-8.45

Dividend yield

—

Beta

0.70

Avg. volume

853.8K

Forecasts

8 analyst ratings

Zenas BioPharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $1.88BP/E —
  $15.86$50.81
• STOK

  Stoke Therapeutics Inc. Common Stock

  $31.61

  ▼ 3.01%
  Market cap $1.84BP/E —
  $18.8$40.22
• OCUL

  Ocular Therapeutix Inc. Common Stock

  $10.36

  ▼ 4.25%
  Market cap $1.84BP/E —
  $6.23$16.44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32
  benzinga · 8/14/2026

Institutional Ownership

March 31, 2026

Total shares held

55.22M

Total value held

$1.08B

Institutional holders

134